Talzenna União Europeia - inglês - EMA (European Medicines Agency)

talzenna

pfizer europe ma eeig - talazoparib - breast neoplasms - antineoplastic agents - talzenna is indicated as monotherapy for the treatment of adult patients with germline brca1/2 mutations, who have her2-negative locally advanced or metastatic breast cancer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

Lorviqua União Europeia - inglês - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - carcinoma, non-small-cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor.lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Vizimpro União Europeia - inglês - EMA (European Medicines Agency)

vizimpro

pfizer europe ma eeig - dacomitinib monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) activating mutations.

Staquis União Europeia - inglês - EMA (European Medicines Agency)

staquis

pfizer europe ma eeig  - crisaborole - dermatitis, atopic - other dermatological preparations - staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (bsa) affected.

Daurismo União Europeia - inglês - EMA (European Medicines Agency)

daurismo

pfizer europe ma eeig - glasdegib maleate - leukemia, myeloid, acute - antineoplastic agents - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Nyvepria União Europeia - inglês - EMA (European Medicines Agency)

nyvepria

pfizer europe ma eeig  - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).